(NASDAQ: AVDL) Avadel Pharmaceuticals's forecast annual revenue growth rate of 140.3% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.13%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.1%.
Avadel Pharmaceuticals's revenue in 2024 is $27,963,000.On average, 5 Wall Street analysts forecast AVDL's revenue for 2024 to be $14,643,039,805, with the lowest AVDL revenue forecast at $13,269,530,207, and the highest AVDL revenue forecast at $16,014,013,246. On average, 4 Wall Street analysts forecast AVDL's revenue for 2025 to be $26,490,782,874, with the lowest AVDL revenue forecast at $21,738,479,520, and the highest AVDL revenue forecast at $30,270,832,732.
In 2026, AVDL is forecast to generate $34,482,210,254 in revenue, with the lowest revenue forecast at $27,535,407,392 and the highest revenue forecast at $39,337,590,231.